The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial at Mayo Clinic, (Rochester, MN) from 11/2013 to 12/2017. Of 209...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Sameer A., Achenbach, Sara J., Call, Timothy G., Rabe, Kari G., Ding, Wei, Leis, Jose F., Kenderian, Saad S., Chanan‐Khan, Asher A., Koehler, Amber B., Schwager, Susan M., Muchtar, Eli, Fonder, Amie L., McCullough, Kristen B., Nedved, Adrienne N., Smith, Matthew D., Slager, Susan L., Kay, Neil E., Finnes, Heidi D., Shanafelt, Tait D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221301/
https://www.ncbi.nlm.nih.gov/pubmed/32187452
http://dx.doi.org/10.1002/cam4.2998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221301/
https://www.ncbi.nlm.nih.gov/pubmed/32187452
http://dx.doi.org/10.1002/cam4.2998

Ejemplares similares